These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 37691190)

  • 1. Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial Hypertrophy.
    Gao Z; Bao J; Hu Y; Tu J; Ye L; Wang L
    Curr Drug Targets; 2023; 24(13):1009-1022. PubMed ID: 37691190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
    Kashiwagi A; Maegawa H
    J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors: molecular design and potential differences in effect.
    Isaji M
    Kidney Int Suppl; 2011 Mar; (120):S14-9. PubMed ID: 21358697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tubular effects of sodium-glucose cotransporter 2 inhibitors: intended and unintended consequences.
    Dominguez Rieg JA; Xue J; Rieg T
    Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):523-530. PubMed ID: 32701600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.
    Packer M
    J Am Soc Nephrol; 2020 May; 31(5):907-919. PubMed ID: 32276962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
    Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic and renal implications of sodium-glucose cotransporter- 2 inhibitors in type 2 diabetes mellitus.
    Tejedor Jorge A
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():35-43. PubMed ID: 28760224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
    Xu B; Li S; Kang B; Zhou J
    Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus.
    Kambara T; Shibata R; Osanai H; Nakashima Y; Asano H; Sakai K; Murohara T; Ajioka M
    Geriatr Gerontol Int; 2018 Jan; 18(1):108-114. PubMed ID: 28861952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.
    Xiao L; Nie X; Cheng Y; Wang N
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1253-1267. PubMed ID: 34273091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review).
    Chen B; Guo J; Ye H; Wang X; Feng Y
    Mol Med Rep; 2024 May; 29(5):. PubMed ID: 38488029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.
    List JF; Whaley JM
    Kidney Int Suppl; 2011 Mar; (120):S20-7. PubMed ID: 21358698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response.
    Xu B; Li S; Kang B; Fan S; Chen C; Li W; Chen J; He Z; Tang F; Zhou J
    Mol Biol Rep; 2023 Nov; 50(11):9637-9647. PubMed ID: 37819499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose cotransporter 2 inhibitor ameliorates high fat diet-induced hypothalamic-pituitary-ovarian axis disorders.
    Chen X; Huang L; Cui L; Xiao Z; Xiong X; Chen C
    J Physiol; 2022 Nov; 600(21):4549-4568. PubMed ID: 36048516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.